Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Science Board To Review Comparative Effectiveness, Pharmacovigilance, Nanotech

This article was originally published in The Pink Sheet Daily

Executive Summary

The May 20 meeting follows a recent reorganization of the safety functions in the Center for Drug Evaluation and Research.
Advertisement

Related Content

FDA’s Lead-In-Lipstick Testing Completed, Cosmetics Director Says
FDA Funds To Rise Despite Widespread Reductions In 2011 Appropriations
CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal
CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal
God Of Gateways: Will FDA's Massive Janus Database Drive Review Efficiency Or Comparative Effectiveness Research?
FDA’s Sentinel Program Readies For Patrol As Stakeholders Watch For Details

Topics

Advertisement
UsernamePublicRestriction

Register

PS072304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel